The multiple myeloma treatment market is poised for change following FDA's approval of three new drugs within a two-week span in November. Now that Johnson & Johnson/Genmab AS’ Darzalex (daratumumab), Takeda Pharmaceutical Co. Ltd.’s Ninlaro (ixazomib) and Bristol-Myers Squibb Co.’s Empliciti (elotuzumab) have all reached the market, drug makers are scrambling to stake a claim – or hold onto an existing one – in the increasingly competitive market.
Multiple Myeloma Market Snapshot: New Drugs And Big Changes
The multiple myeloma treatment landscape is poised for a shakeup following the FDA approval of three new drugs to treat the incurable cancer, but with all the competition, determining which drugs to use when and in which patients won’t necessarily be straightforward.
More from Clinical Trials
• By
Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.
• By
The policy expectation that the model clinical trial agreements are used without modification is in line requests from industry and the NHS/HSC.
• By
DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.
• By
Pharmaceutical companies need to “pressure test” their clinical development strategies early for health technology assessment purposes, particularly in light of the new EU HTA Regulation, a life sciences consultant says.